Eli Lilly and Company stock reports 48 percent growth with FDA approval

Published on 09/28/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly and Company stock gets a fresh FDA catalyst from September 25, 2026. Q2 revenue reached USD 22.97 billion and full-year guidance is USD 85 billion-87 billion.

Fotorealistischer Blick auf eine generische Plasma-Etch-Maschine mit lila Plasmaschein durch das Sichtfenster im Halbleiter-Reinraum — Lam Research US5324571083 generische Plasma Etch Maschine mit lila Plasma im modernen Reinraum sichtbar, Illustration mit AI erstellt.

Eli Lilly and Company stock was trading at USD 1,188.08 on the NYSE on September 28, 2026, at 10:16 a.m. ET, up USD 4.62 or 0.39 percent from the previous close. The latest company catalyst is an FDA approval that expands Olumiant treatment to adolescents aged 12 and older.

FDA approval expands Olumiant

According to Eli Lilly on September 25, 2026, the FDA approved Olumiant for pediatric patients with severe alopecia areata. The approval was based on 36-week Phase 3 data, with 42 percent of patients receiving the 4 mg dose reaching at least 80 percent scalp hair coverage, compared with 5 percent on placebo.

The same study showed that 37 percent of patients on 4 mg reached at least 90 percent scalp hair coverage, versus 2 percent on placebo. The indication broadens an established medicine while Lilly continues to expand its immunology portfolio.

Quarterly growth remains substantial

In second-quarter 2026, revenue reached USD 22.97 billion, up 48 percent year over year, according to Yahoo Finance. Adjusted EPS was USD 8.38 against a consensus estimate of USD 6.01, while Mounjaro revenue reached USD 9.94 billion, up 91 percent year over year.

Lilly raised its 2026 revenue guidance to USD 85 billion-87 billion from USD 82 billion-85 billion. Adjusted EPS guidance is USD 35.50-36.50, compared with the previous range of USD 35.50-37.00, as acquired research and development charges offset part of the underlying earnings increase.

Analyst target remains above price

MarketBeat lists a Moderate Buy consensus based on 30 analyst ratings and an average twelve-month price target of USD 1,308.39. That target is 10.13 percent above the September 28 price, while the stock remains 8.09 percent below its 52-week high of USD 1,292.65.

NYSE price and valuation

Eli Lilly and Company was trading at USD 1,188.08 on the NYSE on September 28, 2026, with a market capitalization of USD 1.1 trillion and volume of 321,877 shares. Its 52-week range was USD 716.08-1,292.65, making the latest price a market value shaped by both rapid pharmaceutical growth and a premium valuation.